Literature DB >> 32188267

Post-exposure prophylaxis: an underutilized biomedical HIV prevention method among gay, bisexual and other men who have sex with men in China.

Jianhua Hou1, Yumeng Wu2, Lu Xie3, Siyan Meng4, Rong Fu5, Huang Zheng6, Na He4, Xiaojie Huang1, Junjie Xu7, Kathrine Meyers2.   

Abstract

Despite abundant evidence on its safety, tolerability and cost-effectiveness, post-exposure prophylaxis (PEP) has not been officially approved for non-occupational use in China. This study aims to assess awareness of, willingness to use, and actual experience with PEP in gay, bisexual and other men who have sex with men (GBM) in China and to explore potential associations between demographic, behavioral, and psychosocial factors and PEP-related outcomes. We recruited a convenience sample through community venue-based strategies, peer referrals, and online advertisement in four cities of China in 2018. We used bivariable and multivariable logistic regression to test associations between potential predictors and PEP outcomes. Over 60% of men reported having heard of PEP prior to the survey, 70% would be willing to use it if exposed to HIV, and 6% reported having used PEP. Awareness of PEP was associated with higher education, more frequent HIV testing, knowing someone who seroconverted in the past two years, having sex with only men in the past six months, and lower perceived risk of HIV infection. PEP willingness was associated with more frequent HIV testing, being worried about becoming HIV infected, prior awareness and favorable attitudes towards PEP among friends. Findings suggest PEP is an underutilized diomedical HIV prevention intervention among GBM in China. Clinical guidance on non-occupational PEP use, as well as communication campaigns targeting social networks of GBM are needed to address barriers to PEP awareness and uptake.

Entities:  

Keywords:  Biomedical HIV prevention; China; Men who have sex with men; Post-exposure prophylaxis

Mesh:

Substances:

Year:  2020        PMID: 32188267     DOI: 10.1080/09540121.2020.1742864

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  5 in total

1.  Trends in HIV post-exposure prophylaxis following sexual exposure in Brazil (2011-2019).

Authors:  Kennedy Crepalde-Ribeiro; Juliana de Oliveira Costa; Sallie-Anne Pearson; Micheline Rosa Silveira; Jullye Campos Mendes; Simone Furtado Dos Santos; Márcio Afonso Cruz; Maria das Graças Braga
Journal:  AIDS Behav       Date:  2022-07-16

2.  Context and Barriers to the Prescription of Nonoccupational Postexposure Prophylaxis Among HIV Medical Care Providers: National Internet-Based Observational Study in China.

Authors:  Haibo Ding; Zehao Ye; Junjie Xu; Hong Shang; Weiming Tang; Xiaojie Huang; Hui Wang; Sitong Cui; Yongjun Jiang; Wenqing Geng
Journal:  JMIR Public Health Surveill       Date:  2021-03-11

3.  Awareness and Use of Post-exposure Prophylaxis for HIV Prevention Among Men Who Have Sex With Men: A Systematic Review and Meta-Analysis.

Authors:  Junyan Jin; Runsong Sun; Tingting Mu; Taiyi Jiang; Lili Dai; Hongyan Lu; Xianlong Ren; Jing Chen; Jingrong Ye; Lijun Sun; Hao Wu; Tong Zhang; Huachun Zou; Bin Su
Journal:  Front Med (Lausanne)       Date:  2022-01-10

4.  Community-engaged mHealth intervention to increase uptake of HIV pre-exposure prophylaxis (PrEP) among gay, bisexual and other men who have sex with men in China: study protocol for a pilot randomised controlled trial.

Authors:  Chunyan Li; Yuan Xiong; Kathryn E Muessig; Weiming Tang; Haojie Huang; Tong Mu; Xiaokai Tong; Jianxiong Yu; Zeyu Yang; Renslow Sherer; Aniruddha Hazra; Jonathan Lio; Derrick D Matthews; Edwin B Fisher; Linghua Li; Joseph D Tucker
Journal:  BMJ Open       Date:  2022-05-10       Impact factor: 3.006

5.  Acceptability of Pre-Exposure Prophylaxis and Non-Occupational Post-Exposure Prophylaxis among Men Who Have Sex with Men in Guilin, China.

Authors:  Lingmi Zhou; Sawitri Assanangkornchai; Zhaohui Shi; Fusheng Jiang; Dong Yang; Wuxiang Shi
Journal:  Int J Environ Res Public Health       Date:  2022-03-17       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.